New targets and developments in lipoproteins control

Norata, Giuseppe Danilo
May 2013
Research Reports in Clinical Cardiology;May2013, Vol. 4, p77
Academic Journal
Statins provide a very effective approach in reducing plasma cholesterol levels and cardiovascular risk. However, the proportion of patients who fail to achieve desirable plasma lipid levels ranges from 16%-53%, worldwide. This percentage reaches up to 80% in patients with familial hypercholesterolemia. Additionally, many patients are unable to tolerate statins, particularly at the highest approved dose level. New treatments that aggressively reduce lipid levels in patients with severe hypercholesterolemia, or those unable to reach their lipid targets, are therefore required. The most promising approaches in this context, such as inhibitors of the synthesis of apolipoprotein B (apoB) containing lipoproteins (apoB silencing or microsomal triglyceride transfer protein [MTP] inhibition) or proprotein convertase subtilisin/kexin type 9 (PCSK9) blockers, all decrease low-density lipoprotein (LDL) extensively. Increasing low levels of high-density lipoprotein (HDL) cholesterol via cholesteryl ester transfer protein inhibitors or apolipoprotein A-1 (ApoA-1) inducers and improving their quality with HDL or ApoA-1 mimetics represent also important options. Drugs affecting HDL, however, may not be all alike and require adequate scrutiny of the mechanisms involved. Until we have a better understanding of these issues, further LDL lowering in high-risk patients represents the soundest approach.


Related Articles

  • HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. Barter, Philip; Gotto, Antonio M.; LaRosa, John C.; Maroni, Jaman; Szarek, Michael; Grundy, Scott M.; Kastelein, John J.P.; Bittner, Vera; Fruchart, Jean-Charles // New England Journal of Medicine;9/27/2007, Vol. 357 Issue 13, p1301 

    Background: High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol. Methods: A post hoc analysis of the recently...

  • The effects of phytosterols/stanols on blood lipid profiles: a systematic review with meta-analysis. Ting Wu; Jia Fu; Yuexin Yang; Lishi Zhang; Junhua Han // Asia Pacific Journal of Clinical Nutrition;Jun2009, Vol. 18 Issue 2, p179 

    The objective of this work is to conduct a systematic review that investigates the efficacy of phytosterols/stanols in lowering lipid concentration in individuals with non-familial hypercholesterolemia. Randomized controlled intervention trials were identified through selected international...

  • Rosuvastatin reigns supreme for hypercholesterolaemia.  // PharmacoEconomics & Outcomes News;11/3/2007, Issue 540, p5 

    The article focuses on a study on the cost effectiveness of rosuvastatin for the treatment of hypercholesterolaemia in Canada. It states that the cost effectiveness of rosuvastatin against atorvastatin, pravastatin and simvastatin among patients with hypercholesterolaemia was evaluated. It cites...

  • Pharmacotherapy of Mixed Hyperlipidemia with Ezetimibe-Fenofibrate Combination Therapy. Farnier, Michel // Clinical Medicine: Therapeutics;2009, Issue 1, p1703 

    Mixed hyperlipidemia is a frequent atherogenic dyslipidemia characterized by elevated triglycerides, low HDL cholesterol levels, and excess of small, dense LDL particles, often with elevated apolipoproteinB and non-HDL cholesterol concentrations. Although statins are the drug of first choice,...

  • JUPITER: HDL not predictive of residual vascular risk among patients with low LDL levels.  // Cardiology Today;Sep2010, Vol. 13 Issue 9, p29 

    The article focuses on a study which suggests that concentrations of high density lipoproteins (HDL) were not indicative of residual vascular risk in individuals with low density lipoproteins who received statin therapy.

  • The Scandinavian Simvastatin Survival Study.  // Pulse;1/27/2010, Vol. 70 Issue 2, p33 

    The article presents a study on the effects of long-term simvastatin therapy on chronic heart disease (CHD) in Scandinavia. The randomized trial aims to demonstrate a positive association between hypercholesterolaemia and CHD. The study found that simvastatin therapy reduced cholesterol low...

  • Pitavastatin: evidence for its place in treatment of hypercholesterolemia. Alagona, Jr, Peter // Core Evidence;2010, Vol. 5 Issue 1, p91 

    Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, are the most potent pharmacologic agents for lowering total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). They have become an accepted standard of care in the treatment of patients with known...

  • Natural Methods To Control Cholesterol. Wiggins, Susan // Life Extension;May2015, p30 

    The article describes natural methods for controlling cholesterol levels in the blood. Topics covered include statin drugs used for lowering low-density lipoprotein cholesterol (LDL-C) while extracts from artichoke leaf can increase high-density lipoprotein cholesterol (HDL-C) with no adverse...

  • Effect of soy and milk protein supplementation on serum lipid levels: a randomized controlled trial. Wofford, M R; Rebholz, C M; Reynolds, K; Chen, J; Chen, C-S; Myers, L; Xu, J; Jones, D W; Whelton, P K; He, J // European Journal of Clinical Nutrition;Apr2012, Vol. 66 Issue 4, p419 

    Background/Objective:Previous clinical trials have documented that soy protein reduces low-density lipoprotein cholesterol and increases high-density lipoprotein (HDL) cholesterol compared with milk protein. However, the effect of soy protein on lipids compared with carbohydrate has not been not...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics